KALV
Kalvista Pharmaceuticals Inc
NASDAQ · Biotechnology
$14.90
+0.50 (+3.47%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 272.43M | 275.70M | 294.93M |
| Net Income | -77,974,346 | -85,417,882 | -94,496,772 |
| EPS | — | — | — |
| Profit Margin | -28.6% | -31.0% | -32.0% |
| Rev Growth | +3.3% | +15.2% | -10.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 33.61M | 40.44M | 36.10M |
| Total Equity | 463.75M | 471.36M | 451.03M |
| D/E Ratio | 0.07 | 0.09 | 0.08 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -125,574,606 | -125,457,307 | -124,623,061 |
| Free Cash Flow | -59,177,907 | -68,220,346 | -69,677,831 |